LeonaBio (LONA) Change in Accured Expenses (2019 - 2026)

LeonaBio (LONA) has reported Change in Accured Expenses for 8 consecutive years, with -$3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 56.08% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$17.0 million (down 67.94% YoY), while the FY2025 annual figure was -$21.3 million, down 271.1% from the prior year.
• Change in Accured Expenses climbed to -$3.4 million in Q1 2026 per LONA's latest filing, from -$11.0 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $6.9 million in Q3 2023 and bottomed at -$11.0 million in Q4 2025.
• Historically, Change in Accured Expenses has averaged -$1.2 million across 5 years, with a median of $164000.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 1100.17% — and 2024, when it sank 2325.0%.
• LeonaBio's Change in Accured Expenses stood at $1.2 million in 2022, then sank by 82.02% to $208000.0 in 2023, then tumbled by 2325.0% to -$4.6 million in 2024, then plunged by 136.73% to -$11.0 million in 2025, then jumped by 69.31% to -$3.4 million in 2026.
• Business Quant data shows LONA's Change in Accured Expenses at -$3.4 million in Q1 2026, -$11.0 million in Q4 2025, and -$207000.0 in Q3 2025.